$80MSeries A, 28 October 2025
$80M launch financing including a Series A advances lead candidate ZAG-101 for type 1 diabetes toward the clinic.
- Amount
- $80M
- Stage
- Series A
- Announced
- 28 October 2025
- Lead
- Polaris Partners
- Other investors
- T1D Fund, Mission BioCapital, AbbVie Ventures, Lightspeed Ventures, Sanofi Ventures, Regeneron Ventures, Boxer Capital
- Use of funds
- $80M launch financing including a Series A advances lead candidate ZAG-101 for type 1 diabetes toward the clinic.
- Checked
- Announced by the company
- Sources
- Zag Bio closes $80M Series A (thymus-targeted medicines) (date approx) drug-dev.com
Zag Bio closes $80M Series A (thymus-targeted medicines) (date approx) news.crunchbase.com